STOCK TITAN

GSK plc (GSK) president logs notional ADS acquisition in executive savings plan

(Neutral)
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

GSK plc reports a transaction by senior manager Maya Martinez‑Davis, who serves as President. She acquired 9.407 notional American Depositary Shares (ADS) within her GSK Executive Supplemental Savings Plan account at a price of $50.7600 per ADS.

The notional ADS are linked to GSK’s ADS and were acquired on 22 July 2026 on the New York Stock Exchange (XNYS). The transaction is described as a single transaction in ADS with ISIN US37733W2044.

Positive

  • None.

Negative

  • None.
ADS volume acquired 9.407 ADS Notional ADS allocated to GSK Executive Supplemental Savings Plan account
ADS price $50.7600 per ADS Price for the notional ADS acquisition within the plan
Transaction date 2026-07-22 Date of the notional ADS acquisition on XNYS
Commission file number 001-15170 SEC file number associated with GSK plc
American Depositary Shares financial
"Description of the financial instrument | American Depositary Shares ('ADS')"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
notional ADS financial
"Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive"
GSK Executive Supplemental Savings Plan financial
"within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account"
PDMR regulatory
"Details of PDMR/person closely associated with them ('PCA')"
A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did GSK (GSK) report involving Maya Martinez-Davis?

GSK reported that Maya Martinez‑Davis, who serves as President, acquired 9.407 notional ADS within her GSK Executive Supplemental Savings Plan account at $50.7600 per ADS, linked to GSK American Depositary Shares.

What type of security was involved in the GSK (GSK) transaction?

The transaction involved American Depositary Shares (ADS), identified by ISIN US37733W2044. These were acquired as notional ADS within an executive supplemental savings plan rather than as directly held ordinary shares.

What was the price and volume in the GSK (GSK) insider ADS transaction?

The reported transaction covered 9.407 notional ADS at a price of $50.7600 per ADS. It is described as a single transaction in the company’s executive supplemental savings plan framework.

On what date did the GSK (GSK) notional ADS acquisition take place?

The notional ADS acquisition took place on 22 July 2026. GSK states that on this date, 9.407 notional American Depositary Shares linked to GSK were allocated to Maya Martinez‑Davis’s supplemental savings plan account.

Where was the GSK (GSK) ADS transaction conducted?

The transaction was conducted on the New York Stock Exchange (XNYS). GSK identifies XNYS as the place of the transaction for the 9.407 notional American Depositary Shares linked to its listed ADS.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of July 2026
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
GSK plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Maya Martinez-Davis
 
b)
Position/status
President, US
 
c)
Initial notification/ amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADS')
 
ISIN: US37733W2044
 
b)
Nature of the transaction
Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account
 
c)
Price(s) and volume(s)
Price(s)
 
Volume(s)
$50.7600
 
9.407
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
 
Price
 
 
e)
Date of the transaction
2026-07-22
 
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
 
 
Registered in England & Wales:
No. 3888792
 
 
Registered Office:
79 New Oxford Street
London
WC1A 1DG
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: July 24, 2026
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc